National Cancer Institute (NCI)

Why trials sponsored by National Cancer Institute (NCI) stopped, in this sample of ClinicalTrials.gov.

47 stopped trials with a clear reason; 91% ended for non-scientific reasons.

Trials

• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  NCT06694454 · SUSPENDED · other
  “Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.”
• Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
  NCT06888323 · SUSPENDED · manufacturing supply
  “Drug Supply Issues”
• CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
  NCT06730100 · WITHDRAWN · slow accrual
  “no accruals”
• Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
  NCT05554354 · TERMINATED · slow accrual
  “Other - slow accrual”
• Oral Iloprost for the Prevention of Lung Cancer In Former Smokers
  NCT05411107 · WITHDRAWN · manufacturing supply
  “Agent is not available”
• Non-Viral TCR Gene Therapy
  NCT04102436 · WITHDRAWN · manufacturing supply
  “Difficulty with availability of GLP-grade reagents for manufacturing.”
• A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
  NCT05711628 · WITHDRAWN · logistics pi
  “Other - Protocol moved to Withdrawn”
• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
  NCT04538378 · TERMINATED · slow accrual
  “Closed due to slow accrual.”
• Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
  NCT04840615 · TERMINATED · slow accrual
  “Study was closed early due to slow accrual.”
• E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer
  NCT04015336 · TERMINATED · logistics pi
  “Logistical challenges”
• Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
  NCT04034251 · TERMINATED · funding business
  “Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment in another study.”
• Tocilizumab for Patients With Cancer and COVID-19 Disease
  NCT04370834 · TERMINATED · funding business
  “Other - Randomized data no longer support continuation”
• Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
  NCT03727841 · TERMINATED · funding business
  “The pharmaceutical company decided to close their program evaluating the study agent, Marizomib.”
• LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT04027946 · TERMINATED · slow accrual
  “Study was terminated due to slow accrual.”
• Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
  NCT03759184 · TERMINATED · slow accrual
  “The study was closed after \> 1 year of inactivity.”
• The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk Tradeoffs
  NCT02874053 · WITHDRAWN · logistics pi
  “PI left the NIH”
• Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
  NCT03794297 · WITHDRAWN · slow accrual
  “Inadequate accrual rate”
• Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
  NCT03345784 · TERMINATED · slow accrual
  “Inadequate accrual rate”
• Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
  NCT02899728 · TERMINATED · slow accrual
  “Inadequate accrual rate”
• Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
  NCT03217253 · WITHDRAWN · manufacturing supply
  “Other - Drug Manufacturer decision to close study”
• Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  NCT03206047 · TERMINATED · manufacturing supply
  “The study was terminated due to a shortage of the drug supply.”
• Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
  NCT03223662 · TERMINATED · logistics pi
  “Principal Investigator left the NIH.”
• Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
  NCT02791919 · WITHDRAWN · logistics pi
  “Other - Protocol moved to Disapproved”
• Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
  NCT03189108 · TERMINATED · logistics pi
  “PI left NIH”
• Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
  NCT02192541 · TERMINATED · funding business
  “Drug supplier suspended further clinical development of Ganetespib”
• Rapid Autopsy and Procurement of Cancer Tissue
  NCT01851395 · TERMINATED · logistics pi
  “PI departure.”
• Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
  NCT01856322 · TERMINATED · slow accrual
  “The trial was prematurely closed due to lack of accrual.”
• Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
  NCT01810913 · SUSPENDED · slow accrual
  “Other - Assessing accrual feasibility”
• TRC105 for Recurrent Glioblastoma
  NCT01778530 · TERMINATED · slow accrual
  “Study was terminated due to poor accrual.”
• Ruxolitinib for Adult T-Cell Leukemia
  NCT01712659 · TERMINATED · safety
  “The adult T-cell leukemia (ATL) research program was terminated after the death of the T-cell malignancy group Lead investigator.”
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
  NCT01583686 · TERMINATED · slow accrual
  “Study terminated due to slow/insufficient accrual.”
• Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
  NCT01495572 · TERMINATED · slow accrual
  “Due to slow accrual, the investigator decided to close the study.”
• Imaging Study for FdCyd and THU Cancer Treatment
  NCT01479348 · TERMINATED · slow accrual
  “Slow, insufficient accrual.”
• Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
  NCT01369888 · TERMINATED · safety
  “Closed this protocol due to autoimmune toxicity.”
• Saracatinib in Treating Patients With Prostate Cancer
  NCT01267266 · TERMINATED · slow accrual
  “Per protocol, study was terminated due to low rate of randomized patients.”
• Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
  NCT01238146 · WITHDRAWN · slow accrual
  “No patients accrued.”
• Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
  NCT01145508 · TERMINATED · slow accrual
  “Poor accrual”
• Pioglitazone for Oral Premalignant Lesions
  NCT00951379 · TERMINATED · slow accrual
  “Due to slow accrual.”
• Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
  NCT00984165 · TERMINATED · slow accrual
  “Terminated due to slow accrual, PI left NIH and primary endpoint not met.”
• A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
  NCT00923247 · TERMINATED · slow accrual
  “Terminated due to slow accrual,primary endpoint reached \& investigator left NIH.”
• Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
  NCT00522392 · TERMINATED · slow accrual
  “Slow accrual”
• Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
  NCT00499369 · TERMINATED · slow accrual
  “Due to inadequate accrual, study was terminated and limited outcome data was reported.”
• Bevacizumab and Irinotecan to Treat Brain Tumors
  NCT00393094 · TERMINATED · slow accrual
  “Terminated due to the limitations of accrual.”
• Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
  NCT00096109 · TERMINATED · slow accrual
  “Closed to accrual before all 12 planned patients were enrolled.”
• Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
  NCT00074490 · TERMINATED · slow accrual
  “Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2”
• A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
  NCT00020683 · TERMINATED · manufacturing supply
  “Cancer Therapy Evaluation Program's (CTEP's) termination of drug supply”
• Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer
  NCT00004859 · TERMINATED · futility
  “Trial was stopped early for futility”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.